Photodynamic Therapy and Non-Melanoma Skin Cancer

Liezel L Griffin, John T Lear, Liezel L Griffin, John T Lear

Abstract

Non-melanoma skin cancer (NMSC) is the most common malignancy among the Caucasian population. Photodynamic therapy (PDT) is gaining popularity for the treatment of basal cell carcinoma (BCC), Bowen's disease (BD) and actinic keratosis (AK). A topical or systemic exogenous photosensitiser, results in selective uptake by malignant cells. Protoporphyrin IX (PpIX) is produced then activated by the introduction of a light source. Daylight-mediated MAL (methyl aminolaevulinate) PDT for AKs has the advantage of decreased pain and better patient tolerance. PDT is an effective treatment for superficial BCC, BD and both individual and field treatment of AKs. Excellent cosmesis can be achieved with high patient satisfaction. Variable results have been reported for nodular BCC, with improved outcomes following pretreatment and repeated PDT cycles. The more aggressive basisquamous, morphoeic infiltrating subtypes of BCC and invasive squamous cell carcinoma (SCC) are not suitable for PDT. Prevention of "field cancerization" in organ transplant recipients on long-term immunosuppression and patients with Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a promising development. The optimisation of PDT techniques with improved photosensitiser delivery to target tissues, new generation photosensitisers and novel light sources may expand the future role of PDT in NMSC management.

Keywords: Gorlin syndrome; actinic keratosis; basal cell carcinoma; field cancerization; non-melanoma skin cancer; organ transplant recipients; photodynamic therapy.

Conflict of interest statement

J.T.L. has accepted honoraria for speaking at meetings by Leo, Galderma, Almirall, Astellas and GlaxoSmithKline.

Figures

Figure 1
Figure 1
Superficial basal cell carcinoma before and after treatment with photodynamic therapy.

References

    1. Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol. 2012;166:1069–1080. doi: 10.1111/j.1365-2133.2012.10830.x.
    1. Roewert-Huber J., Lange-Asschenfeldt B., Stockfleth E., Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br. J. Dermatol. 2007;157:47–51. doi: 10.1111/j.1365-2133.2007.08273.x.
    1. Fantini F., Greco A., Del Giovane C., Cesinaro A.M., Venturini M., Zane C., Surrenti T., Peris K., Calzavara-Pinton P.G. Photodynamic therapy for basal cell carcinoma: Clinical and pathological determinants of response. J. Eur. Acad. Dermatol. Venereol. 2011;25:896–901. doi: 10.1111/j.1468-3083.2010.03877.x.
    1. Griffin L.L., Ali F.R., Lear J.T. Non-melanoma skin cancer. Clin. Med. 2016;16:62–65. doi: 10.7861/clinmedicine.16-1-62.
    1. Morton C.A., Szeimies R.M., Sidoroff A., Braathen L.R. European guidelines for topical photodynamic therapy part 1: Treatment delivery and current indications actinic keratoses, Bowen's disease, basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 2013;27:536–544. doi: 10.1111/jdv.12031.
    1. Szeimies R.M., Morton C.A., Sidoroff A., Braathen L.R. Photodynamic therapy for non-melanoma skin cancer. Acta Derm. Venereol. 2005;85:483–490.
    1. Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin. IX. basic principles and present clinical-experience. J. Photochem. Photobiol. 1990;6:143–148. doi: 10.1016/1011-1344(90)85083-9.
    1. Gollnick S.O., Evans S.S., Baumann H., Owczarczak B., Maier P., Vaughan L., Wang W.C., Unger E., Henderson B.W. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br. J. Cancer. 2003;88:1772–1779. doi: 10.1038/sj.bjc.6600864.
    1. Rhodes L.E., de Rie M., Enstrom Y., Groves R., Morken T., Goulden V., Wong G.A.E., Grob J.J., Varma S., Wolf P. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma—Results of a multicenter randomized prospective trial. Archives Dermatol. 2004;140:17–23. doi: 10.1001/archderm.140.1.17.
    1. Brown S.B., Brown E.A., Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5:497–508. doi: 10.1016/S1470-2045(04)01529-3.
    1. Braakhuis B.J.M., Tabor M.P., Kummer J.A., Leemans C.R., Brakenhoff R.H. A genetic explanation of Slaughter’s concept of field cancerization: Evidence and clinical implications. Cancer Res. 2003;63:1727–1730.
    1. Braathen L.R. Photodynamic therapy: Increasing acceptance through reduction of adverse reactions. Br. J. Dermatol. 2014;171:1298–1299. doi: 10.1111/bjd.13395.
    1. Buinauskaite E., Zalinkevicius R., Buinauskiene J., Valiukeviciene S. Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: Randomized controlled trial. Photodermatol. Photoimmunol. Photomed. 2013;29:173–181. doi: 10.1111/phpp.12044.
    1. Lui H., Hobbs L., Tope W.D., Lee P.K., Elmets C., Provost N., Chan A., Neyndorff H., Su X.Y., Jain H., et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes—Two-year results evaluating tumor response and cosmetic outcomes. Arch. Dermatol. 2004;140:26–32. doi: 10.1001/archderm.140.1.26.
    1. Dabrowski J.M., Arnaut L.G. Photodynamic therapy (PDT) of cancer: from local to systemic treatment. Photochem. Photobiol. Sci. 2015;14:1765–1780. doi: 10.1039/C5PP00132C.
    1. Horlings R.K., Terra J.B., Witjes M.J.H. mTHPC mediated, systemic photodynamic therapy (PDT) for nonmelanoma skin cancers: Case and literature review. Lasers Surg. Med. 2015;47:779–787. doi: 10.1002/lsm.22429.
    1. Stender I.M., BechThomsen N., Poulsen T., Wulf H.C. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem. Photobiol. 1997;66:493–496. doi: 10.1111/j.1751-1097.1997.tb03178.x.
    1. Liu Y.N., Viau G., Bissonnette R. Multiple large-surface photodynamic therapy sessions with topical or systemic aminolevulinic acid and blue light in UV-exposed hairless mice. J. Cutan. Med. Surg. 2004;8:131–139. doi: 10.1007/s10227-004-0117-5.
    1. Togsverd-Bo K., Lerche C.M., Poulsen T., Wulf H.C., Haedersdal M. Photodynamic therapy with topical methyl- and hexylaminolevulinate for prophylaxis and treatment of UV-induced SCC in hairless mice. Exp. Dermatol. 2010;19:E166–E172. doi: 10.1111/j.1600-0625.2009.01035.x.
    1. Wiegell S.R., Wulf H.C., Szeimies R.M., Basset-Seguin N., Bissonnette R., Gerritsen M.J.P., Gilaberte Y., Calzavara-Pinton P., Morton C.A., Sidoroff A., et al. Daylight photodynamic therapy for actinic keratosis: An international consensus. J. Eur. Acad. Dermatol. Venereol. 2012;26:673–679. doi: 10.1111/j.1468-3083.2011.04386.x.
    1. Wiegell S.R., Haedersdal M., Philipsen P.A., Eriksen P., Enk C.D., Wulf H.C. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br. J. Dermatol. 2008;158:740–746. doi: 10.1111/j.1365-2133.2008.08450.x.
    1. Philipp-Dormston W.G., Sanclemente G., Torezan L., Clementoni M.T., Le Pillouer-Prost A., Cartier H., Szeimies R.M., Bjerring P. Daylight photodynamic therapy with MAL cream for large-scale photodamaged skin based on the concept of "actinic field damage": Recommendations of an international expert group. J. Eur. Acad. Dermatol. Venereol. 2016;30:8–15. doi: 10.1111/jdv.13327.
    1. Wiegell S.R., Fabricius S., Heydenreich J., Enk C.D., Rosso S., Baeumler W., Baldursson B.T., Wulf H.C. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br. J. Dermatol. 2013;168:186–191. doi: 10.1111/j.1365-2133.2012.11200.x.
    1. Lacour J.P., Ulrich C., Gilaberte Y., Von Felbert V., Basset-Seguin N., Dreno B., Girard C., Redondo P., Serra-Guillen C., Synnerstad I., et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: A randomised, investigator-blinded, controlled, phase III study throughout Europe. J. Eur. Acad. Dermatol. Venereol. 2015;29:2342–2348. doi: 10.1111/jdv.13228.
    1. Cantisani C., Paolino G., Cantoresi F., Calvieri S. Daylight photodynamic therapy for the treatment of actinic keratosis. J. Am. Acad. Dermatol. 2015;72:AB214.
    1. Rubel D.M., Spelman L., Murrell D.F., See J.A., Hewitt D., Foley P., Bosc C., Kerob D., Kerrouche N., Wulf H.C., et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: A randomized controlled trial. Br. J. Dermatol. 2014;171:1164–1171. doi: 10.1111/bjd.13138.
    1. Wiegell S.R., Fabricius S., Stender I.M., Berne B., Kroon S., Andersen B.L., Mork C., Sandberg C., Jemec G.B.E., Mogensen M., et al. A randomized, multicentre study of directed daylight exposure times of 11/2 vs. 21/2 h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br. J. Dermatol. 2011;164:1083–1090. doi: 10.1111/j.1365-2133.2011.10209.x.
    1. Fargnoli M.C., Piccioni A., Neri L., Tambone S., Pellegrini C., Peris K. Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient, prospective, comparison study in Italy. J. Eur. Acad. Dermatol. Venereol. 2015;29:1926–1932. doi: 10.1111/jdv.13076.
    1. Neittaanmaki-Perttu N., Karppinen T.T., Gronroos M., Tani T.T., Snellman E. Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate. Br. J. Dermatol. 2014;171:1172–1180. doi: 10.1111/bjd.13326.
    1. Fiechter S., Skaria A., Nievergelt H., Anex R., Borradori L., Parmentier L. Facial basal cell carcinomas recurring after photodynamic therapy: A retrospective analysis of histological subtypes. Dermatology. 2012;224:346–351. doi: 10.1159/000339335.
    1. Szeimies R.M., Ibbotson S., Murrell D.F., Rubel D., Frambach Y., de Berker D., Dummer R., Kerrouche N., Villemagne H. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J. Eur. Acad. Dermatol. Venereol. 2008;22:1302–1311. doi: 10.1111/j.1468-3083.2008.02803.x.
    1. Basset-Seguin N., Ibbotson S.H., Emtestam L., Tarstedt M., Morton C., Maroti M., Calzavara-Pinton P., Varma S., Roelandts R., Wolf P. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: A 5 year randomized trial. Euro. J. Dermatol. 2008;18:547–553.
    1. Arits A.H.M.M., Mosterd K., Essers B.A.B., Spoorenberg E., Sommer A., de Rooij M.J.M., van Pelt H.P., Quaedvlieg P.J., Krekels G.A., van Neer P.A., et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14:647–654. doi: 10.1016/S1470-2045(13)70143-8.
    1. Roozeboom M.H., Arits A.H.H.M., Nelemans P.J., Kelleners-Smeets N.W.J. Overall treatment success after treatment of primary superficial basal cell carcinoma: A systematic review and meta-analysis of randomized and nonrandomized trials. Br. J. Dermatol. 2012;167:733–756. doi: 10.1111/j.1365-2133.2012.11061.x.
    1. Foley P., Freeman M., Menter A., Siller G., El-Azhary R.A., Gebauer K., Lowe N.J., Jarratt N.T., Murrell D.F., Rich P., et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: Results of two randomized studies. Inter. J. Dermatol. 2009;48:1236–1245. doi: 10.1111/j.1365-4632.2008.04022.x.
    1. Tope W.D., Menter A., El-Azhary R.A., Lowe N.J. Comparison of topical methylaminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular basal cell carcinoma. J. Am. Acad. Dermatol. 2004;50:123. doi: 10.1016/j.jaad.2003.10.419.
    1. Rhodes L.E., de Rie M.A., Leifsdottir R., Yu R.C., Bachmann I., Goulden V., Wong G.A., Richard M.A., Anstey A., Wolf P. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs. surgery for nodular basal cell carcinoma. Arch. Dermatol. 2007;143:1131–1136. doi: 10.1001/archderm.143.9.1131.
    1. Mosterd K., Thissen M., Nelemans P., Kelleners-Smeets N.W.J., Janssen R., Broekhof K., Neumann H.A., Steijlen P.M., Kuijpers D.I. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: Results of a randomized controlled trial. Br. J. Dermatol. 2008;159:864–870. doi: 10.1111/j.1365-2133.2008.08787.x.
    1. Cosgarea R., Susan M., Crisan M., Senila S. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 2013;27:980–984. doi: 10.1111/j.1468-3083.2012.04619.x.
    1. Roozeboom M.H., van Kleef L., Arits A.H.M.M., Mosterd K., Winnepenninckx V.J.L., van Marion A.M.W., Nelemans P.J., Kelleners-Smeets N.W. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU) J. Am. Acad. Dermatol. 2015;73:93–98. doi: 10.1016/j.jaad.2015.03.048.
    1. Christensen E., Mork C., Foss O.A. Pre-treatment deep curettage can significantly reduce tumour thickness in thick Basal cell carcinoma while maintaining a favourable cosmetic outcome when used in combination with topical photodynamic therapy. J. Skin Cancer. 2011 doi: 10.1155/2011/240340. Article ID 240340.
    1. Gerritsen M.J.P., Smits T., Kleinpenning M.M., van de Kerkhof P.C.M., van Erp P.E.J. Pretreatment to Enhance Protoporphyrin IX Accumulation in Photodynamic Therapy. Dermatology. 2009;218:193–202. doi: 10.1159/000183753.
    1. Christensen E., Mork C., Skogvoll E. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br. J. Dermatol. 2012;166:1342–1348. doi: 10.1111/j.1365-2133.2012.10878.x.
    1. Angel Rodriguez-Prieto M., Gonzalez-Sixto B., Perez-Bustillo A., Alonso-Alonso T., Ortega-Valin L., Martinez-Valderrabano V., González-Morán A., García Doval I. Photodynamic therapy with intralesional photosensitizer and laser beam application: An alternative treatment for nodular basal cell carcinoma. J. Am. Acad. Dermatol. 2012;67:E134–E136. doi: 10.1016/j.jaad.2011.10.021.
    1. Haak C.S., Togsverd-Bo K., Thaysen-Petersen D., Wulf H.C., Paasch U., Anderson R.R., Haedersdal M. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas—A randomized clinical trial. Br. J. Dermatol. 2015;172:215–222. doi: 10.1111/bjd.13166.
    1. Kuijpers D.I.M., Smeets N.W.J., Krekels G.A.M., Thissen M. Photodynamic therapy as adjuvant treatment of extensive basal cell carcinoma treated with Mohs micrographic surgery. Dermatol. Surg. 2004;30:794–798.
    1. Al-Niaimi F., Sheth N., Kurwa H.A., Mallipeddi R. Photodynamic therapy followed by mohs micrographic surgery compared to mohs micrographic surgery alone for the treatment of basal cell carcinoma: Results of a pilot single-blinded randomised controlled trial. J. Cutan. Aesthet. Surg. 2015;8:88–91. doi: 10.4103/0974-2077.158443.
    1. Glogau R.G. The risk of progression to invasive disease. J. Am. Acad. Dermatol. 2000;42:23–24. doi: 10.1067/mjd.2000.103339.
    1. Ko D.Y., Jeon S.Y., Kim K.H., Song K.H. Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: A randomized, comparative, prospective study. J. Eur. Acad. Dermatol. Venereol. 2014;28:1529–1539. doi: 10.1111/jdv.12334.
    1. Morton C., Campbell S., Gupta G., Keohane S., Lear J., Zaki I., Walton S., Kerrouche N., Thomas G., Soto P. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: A multicentre, randomized controlled study. Br. J. Dermatol. 2006;155:1029–1036. doi: 10.1111/j.1365-2133.2006.07470.x.
    1. Lucena S.R., Salazar N., Gracia-Cazana T., Zamarron A., Gonzalez S., Juarranz A., Gilaberte Y. Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer. Int. J. Mol. Sci. 2015;16:25912–25933. doi: 10.3390/ijms161025912.
    1. Braathen L.R., Szeimies R.-M., Basset-Seguin N., Bissonnette R., Foley P., Pariser D., Roelandts R., Wennberg A.M., Morton C.A. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. J. Am. Acad. Dermatol. 2007;56:125–143. doi: 10.1016/j.jaad.2006.06.006.
    1. Tschen E.H., Wong D.S., Pariser D.M., Dunlap F.E., Houihan A., Ferdon M.B., the Phase IV ALA-PDT Actinic Keratosis Study Group Photodynamic therapy using aminotaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: Phase IV multicentre clinical trial with 12-month follow up. Br. J. Dermatol. 2006;155:1262–1269. doi: 10.1111/j.1365-2133.2006.07520.x.
    1. Hauschild A., Stockfleth E., Popp G., Borrosch F., Bruening H., Dominicus R., Mensing H., Reinhold U., Reich K., Moor A.C., et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: Results of two randomized controlled phase III studies. Br. J. Dermatol. 2009;160:1066–1074. doi: 10.1111/j.1365-2133.2009.09040.x.
    1. Freeman M., Vinciullo C., Francis D., Spelman L., Nguyen R., Fergin P., Thai K.E., Murrell D., Weightman W., Anderson C., et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study. J. Dermatol. Treat. 2003;14:99–106. doi: 10.1080/09546630310012118.
    1. Kaufmann R., Spelman L., Weightman W., Reifenberger J., Szeimies R.M., Verhaeghe E., Kerrouche N., Sorba V., Villemagne H., Rhodes L.E. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br. J. Dermatol. 2008;158:994–999. doi: 10.1111/j.1365-2133.2008.08488.x.
    1. Kurwa H.A., Yong-Gee S.A., Seed P.T., Markey A.C., Barlow R.J. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J. Am. Acad. Dermatol. 1999;41:414–418. doi: 10.1016/S0190-9622(99)70114-3.
    1. Hadley J., Tristani-Firouzi P., Hull C., Florell S., Cotter M., Hadley M. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol. Surg. 2012;38:722–727. doi: 10.1111/j.1524-4725.2012.02340.x.
    1. Sotiriou E., Apalla Z., Maliamani F., Zaparas N., Panagiotidou D., Ioannides D. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J. Eur. Acad. Dermatol. Venereol. 2009;23:1061–1065. doi: 10.1111/j.1468-3083.2009.03259.x.
    1. Serra-Guillen C., Nagore E., Hueso L., Traves V., Messeguer F., Sanmartin O., Llombart B., Requena C., Botella-Estrada R., Guillén C. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: Clinical and histologic outcomes. J. Am. Acad. Dermatol. 2012;66:E131–E137. doi: 10.1016/j.jaad.2011.11.933.
    1. Scola N., Terras S., Georgas D., Othlinghaus N., Matip R., Pantelaki I., Möllenhoff K., Stücker M., Altmeyer P., Kreuter A., et al. A randomized, half-side comparative study of aminolaevulinate photodynamic therapy vs. CO2 laser ablation in immunocompetent patients with multiple actinic keratoses. Br. J. Dermatol. 2012;167:1366–1373. doi: 10.1111/j.1365-2133.2012.11103.x.
    1. Gholam P., Fink C., Bosselmann I., Enk A.H. Retrospective analysis evaluating the effect of a keratolytic and physical pretreatment with salicylic acid, urea and curettage on the efficacy and safety of photodynamic therapy of actinic keratoses with methylaminolaevulinate. J. Eur. Acad. Dermatol. Venereol. 2016;30:619–623. doi: 10.1111/jdv.13449.
    1. Togsverd-Bo K., Haak C.S., Thaysen-Petersen D., Wulf H.C., Anderson R.R., Haedesdal M. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: A randomized clinical trial. Br. J. Dermatol. 2012;166:1262–1269. doi: 10.1111/j.1365-2133.2012.10893.x.
    1. Song H.S., Jung S.-E., Jang Y.H., Kang H.Y., Lee E.-S., Kim Y.C. Fractional carbon dioxide laser-assisted photodynamic therapy for patients with actinic keratosis. Photodermatol. Photoimmunol. Photomed. 2015;31:296–301. doi: 10.1111/phpp.12184.
    1. Szeimies R.M., Hauschild A., Ortland C., Moor A.C.E., Stocker M., Surber C. Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally well to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions. Br. J. Dermatol. 2015;173:1277–1279. doi: 10.1111/bjd.13889.
    1. Szeimies R.M., Radny P., Sebastian M., Borrosch F., Dirschka T., Krahn-Senftleben G., Reich K., Pabst G., Voss D., Foguet M., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br. J. Dermatol. 2010;163:386–394. doi: 10.1111/j.1365-2133.2010.09873.x.
    1. Gracia-Cazana T., Teresa Lopez M., Oncins R., Gilaberte Y. Successful treatment of sequential therapy in digital Bowen’s disease with methyl aminolevulinate photodynamic therapy and topical diclofenac 3% in hyaluronan 2.5% gel. Dermatol. Ther. 2015;28:341–343. doi: 10.1111/dth.12270.
    1. Morton C., Horn M., Leman J., Tack B., Bedane C., Tjioe M., Ibbotson S., Khemis A., Wolf P. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ—Results of a multicenter randomized trial. Arch. Dermatol. 2006;142:729–735. doi: 10.1001/archderm.142.6.729.
    1. Salim A., Leman J.A., McColl J.H., Chapman R., Morton C.A. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br. J. Dermatol. 2003;148:539–543. doi: 10.1046/j.1365-2133.2003.05033.x.
    1. Lopez N., Meyer-Gonzalez T., Herrera-Acosta E., Bosch R., Castillo R., Herrera E. Photodynamic therapy in the treatment of extensive Bowen's disease. J. Dermatol. Treat. 2012;23:428–430. doi: 10.3109/09546634.2011.590789.
    1. Truchuelo M., Fernandez-Guarino M., Fleta B., Alcantara J., Jaen P. Effectiveness of photodynamic therapy in Bowen’s disease: An observational and descriptive study in 51 lesions. J. Eur. Acad. Dermatol. Venereol. 2012;26:868–874. doi: 10.1111/j.1468-3083.2011.04175.x.
    1. Westers-Attema A., Lohman B.G.P.M., van den Heijkant F., Nelemans P.J., Winnepenninckx V.J., Kelleners-Smeets N.W.J., Mosterd K. Photodynamic therapy in Bowen’s disease: Influence of histological features and clinical characteristics on its success. Dermatology. 2015;230:55–61. doi: 10.1159/000366500.
    1. Gracia-Cazana T., Vera-Alvarez J., Juarranz A., Pastushenko I., Salazar N., Gonzalez S., Gilaberte Y. Clinicopathological features of Bowen’s disease resistance to methyl aminolevulinate photodynamic therapy. J. Investig. Dermatol. 2015;135:S100.
    1. Calzavara-Pinton P.G., Venturini M., Sala R., Capezzera R., Parrinello G., Specchia C., Zane C. Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma. Br. J. Dermatol. 2008;159:137–144. doi: 10.1111/j.1365-2133.2008.08593.x.
    1. Gilaberte Y., Milla L., Salazar N., Vera-Alvarez J., Kourani O., Damian A., Rivarola V., Roca M.J., Espada J., González S., et al. Cellular Intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy. J. Investig. Dermatol. 2014;134:2428–2437. doi: 10.1038/jid.2014.178.
    1. Basset-Seguin N., Conzett K.B., Gerritsen M.J.P., Gonzalez H., Haedersdal M., Hofbauer G.F.L., Aguado L., Kerob D., Lear J.T., Piaserico S., et al. Photodynamic therapy for actinic keratosis in organ transplant patients. J. Eur. Acad. Dermatol. Venereol. 2013;27:57–66. doi: 10.1111/j.1468-3083.2011.04356.x.
    1. Wlodek C., Ali F.R., Lear J.T. Use of photodynamic therapy for treatment of actinic keratoses in organ transplant recipients. BioMed. Res. Int. 2013 doi: 10.1155/2013/349526. Article ID 349526.
    1. Ulrich C., Kanitakis J., Stockfleth E., Euvrard S. Skin cancer in organ transplant recipients - Where do we stand today ? Am. J. Transplant. 2008;8:2192–2198. doi: 10.1111/j.1600-6143.2008.02386.x.
    1. Ramsay H.M., Fryer A.A., Hawley C.M., Smith A.G., Nicol D.L., Harden P.N. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br. J. Dermatol. 2002;147:950–956. doi: 10.1046/j.1365-2133.2002.04976.x.
    1. Wennberg A.M., Keohane S., T Lear J., Jemec G., Mork C., Christensen E., Kapp A., Solvsten H., Talm T., Berne B., et al. Results from a 15-month update of a multicentre study of methyl aminolaevulinate photodynamic therapy in immunocompromised organ transplant recipients with nonmelanoma skin cancer. Br. J. Dermatol. 2006;155:57.
    1. Collier N.J., Ali F.R., Lear J.T. Efficacy of photodynamic therapy for treatment of basal cell carcinoma in organ transplant recipients. Lasers Med. Sci. 2015;30:1407–1409. doi: 10.1007/s10103-013-1454-7.
    1. Guleng G.E., Helsing P. Photodynamic therapy for basal cell carcinomas in organ-transplant recipients. Clin. Exp. Dermatol. 2012;37:367–369. doi: 10.1111/j.1365-2230.2011.04248.x.
    1. Dragieva G., Hafner J., Dummer R., Schmid-Grendelmeier P., Roos M., Prinz B.M., Burg G., Binswanger U., Kempf W. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation. 2004;77:115–121. doi: 10.1097/01.TP.0000107284.04969.5C.
    1. Dragieva G., Prinz B.M., Hafner J., Dummer R., Burg G., Binswanger U., Kempf W. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br. J. Dermatol. 2004;151:196–200. doi: 10.1111/j.1365-2133.2004.06054.x.
    1. Togsverd-Bo K., Omland S.H., Wulf H.C., Sorensen S.S., Haedersdal M. Primary Prevention of Skin Dysplasia in Renal Transplant Recipients With Photodynamic Therapy: A Randomized Controlled Trial. Am. J. Transplant. 2015;15:2986–2990. doi: 10.1111/ajt.13358.
    1. Wulf H.C., Pavel S., Stender I., Bakker-Wensveen C.A. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm. Venereol. 2006;86:25–28.
    1. Willey A., Mehta S., Lee P.K. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol. Surg. 2010;36:652–658. doi: 10.1111/j.1524-4725.2009.01384.x.
    1. Girard C., Debu A., Bessis D., Blatiere V., Dereure O., Guillot B. Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: Interest of tumescent anesthesia for pain control in children. J. Eur. Acad. Dermatol. Venereol. 2013;27:E171–E175. doi: 10.1111/j.1468-3083.2012.04538.x.
    1. Loncaster J., Swindell R., Slevin F., Sheridan L., Allan D., Allan E. Efficacy of Photodynamic Therapy as a Treatment for Gorlin Syndrome-related Basal Cell Carcinomas. Clin. Oncol. 2009;21:502–508. doi: 10.1016/j.clon.2009.03.004.
    1. Fai D. MAL-PDT for the treatment of multiple basal cell carcinomas in a patient with Gorlin-Goltz syndrome. J. Invest. Dermatol. 2006;126:S34.
    1. Neves D.R., Ramos D.G., Magalhaes G.M., Rodrigues R.d.C., Alves de Souza J.B. Photodynamic therapy for treatment of multiple lesions on the scalp in nevoid basal cell carcinoma syndrome—Case report. An. Bras. Dermatol. 2010;85:545–548. doi: 10.1590/S0365-05962010000400019.
    1. Madan V., Loncaster J., Allan D., Lear J., Sheridan L., Leach C., Allan E. Systemic photodynamic therapy with Photofrin for naevoid basal cell carcinoma syndrome—A pilot study. Photodiagnosis Photodyn. Ther. 2005;2:273–281. doi: 10.1016/S1572-1000(05)00101-8.
    1. Mougel F., Debarbieux S., Ronger-Savle S., Dalle S., Thomas L. Methylaminolaevulinate Photodynamic therapy in patients with multiple basal cell carcinomas in the setting of gorlin-goltz syndrome or after radiotherapy. Dermatology. 2009;219:138–142. doi: 10.1159/000228316.
    1. Basset-Seguin N., Bissonnette R., Girard C., Haedersdal M., Lear J.T., Paul C., Piaserico S. Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. J. Eur. Acad. Dermatol. Venereol. 2014;28:626–632. doi: 10.1111/jdv.12150.
    1. Alexiades-Armenakas M. The future of photodynamic therapy. Photodyn. Ther. Dermatol. 2011 doi: 10.1007/978-1-4419-1298-5_17.
    1. Neittaanmaki-Perttu N., Gronroos M., Karppinen T.T., Tani T.T., Snellman E. Hexyl-5-aminolaevulinate 0.2% vs. methyl-5-aminolaevulinate 16% daylight photodynamic therapy for treatment of actinic keratoses: Results of a randomized double-blinded pilot trial. Br. J. Dermatol. 2016;174:427–429. doi: 10.1111/bjd.13924.
    1. Attili S.K., Lesar A., McNeill A., Camacho-Lopez M., Moseley H., Ibbotson S., Samuel I.D., Ferguson J. An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. Br. J. Dermatol. 2009;161:170–173. doi: 10.1111/j.1365-2133.2009.09096.x.
    1. Babilas P., Travnik R., Werner A., Landthaler M., Szeimies R.M. Split-face study using two different light sources for topical PDT of actinic keratoses: Non-inferiority of the LED-system. J. Dtsch. Dermatol. Ges. 2008;6:25–33.
    1. Morton C.A., Szeimies R.M., Sidoroff A., Braathen L.R. European guidelines for topical photodynamic therapy part 2: Emerging indications—Field cancerization, photorejuvenation and inflammatory/infective dermatoses. J. Eur. Acad. Dermatol. Venereol. 2013;27:672–629. doi: 10.1111/jdv.12026.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj